


Highlights of This Issue 2045
SMALL MOLECULE THERAPEUTICS

- 2047** **Antitumor Effect of the Atypical Retinoid ST1926 in Acute Myeloid Leukemia and Nanoparticle Formulation Prolongs Lifespan and Reduces Tumor Burden of Xenograft Mice**
Leeanna El-Houjeiri, Walid Saad, Berthe Hayar, Patrick Aouad, Nadim Tawil, Rana Abdel-Samad, Rita Hleihel, Maguy Hamie, Angelo Mancinelli, Claudio Pisano, Hiba El Hajj, and Nadine Darwiche
- 2058** **A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia**
Tamara B. Garcia, Jonathan C. Snedeker, Dmitry Baturin, Lori Gardner, Susan P. Fosmire, Chengjing Zhou, Craig T. Jordan, Sujatha Venkataraman, Rajeev Vibhakar, and Christopher C. Porter
- 2069** **PI3K γ / δ and NOTCH1 Cross-Regulate Pathways That Define the T-cell Acute Lymphoblastic Leukemia Disease Signature**
Evgeni Efimenko, Utpal P. Davé, Irina V. Lebedeva, Yao Shen, Maria J. Sanchez-Quintero, Daniel Diolaiti, Andrew Kung, Brian J. Lannutti, Jianchung Chen, Ronald Realubit, Zoya Niatsetskaya, Vadim Ten, Charles Karan, Xi Chen, Andrea Califano, and Thomas G. Diacovo
- 2083** **Disruption of Aneuploidy and Senescence Induced by Aurora Inhibition Promotes Intrinsic Apoptosis in Double Hit or Double Expressor Diffuse Large B-cell Lymphomas**
Shariful Islam, Wenqing Qi, Carla Morales, Laurence Cooke, Catherine Spier, Eric Weterings, and Daruka Mahadevan
- 2094** **MiR-125b Increases Nasopharyngeal Carcinoma Radioresistance by Targeting A20/NF- κ B Signaling Pathway**
Li-Na Li, Ta Xiao, Hong-Mei Yi, Zhen Zheng, Jia-Quan Qu, Wei Huang, Xu Ye, Hong Yi, Shan-Shan Lu, Xin-Hui Li, and Zhi-Qiang Xiao
- 2107** **The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy**
Céline Clémenson, Cyrus Chargari, Winchygn Liu, Michele Mondini, Charles Ferté, Mike F. Burbridge, Valérie Cattan, Anne Jacquet-Bescond, and Eric Deutsch
- 2120** **Inhibition of Androgen Receptor Nuclear Localization and Castration-Resistant Prostate Tumor Growth by Pyrroloimidazole-based Small Molecules**
Khalid Z. Masoodi, Yadong Xu, Javid A. Dar, Kurtis Eisermann, Laura E. Pascal, Erica Parrinello, Junkui Ai, Paul A. Johnston, Joel B. Nelson, Peter Wipf, and Zhou Wang
- 2130** **Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers**
 Miho J. Fuse, Koutaroh Okada, Tomoko Oh-hara, Hayato Ogura, Naoya Fujita, and Ryohei Katayama
- 2144** **Dual Inhibition of NOX2 and Receptor Tyrosine Kinase by BJ-1301 Enhances Anticancer Therapy Efficacy via Suppression of Autocrine-Stimulatory Factors in Lung Cancer**
Jaya Gautam, Jin-Mo Ku, Sushil Chandra Regmi, Hyunyoung Jeong, Ying Wang, Suhrid Banskota, Myo-Hyeon Park, Tae-gyu Nam, Byeong-Seon Jeong, and Jung-Ae Kim
- 2157** **Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma**
Gaël S. Roth, Zuzana Macek Jilkova, Ayca Zeybek Kuyucu, Keerthi Kurma, Séyédéh Tayébéh Ahmad Pour, Giovanni Abbadessa, Yi Yu, Benoit Busser, Patrice N. Marche, Vincent Leroy, and Thomas Decaens
- 2166** **The DNA-Binding Polyamine Moiety in the Vectorized DNA Topoisomerase II Inhibitor F14512 Alters Reparability of the Consequent Enzyme-Linked DNA Double-Strand Breaks**
Oriane Bombarde, Florence Larminat, Dennis Gomez, Philippe Frit, Carine Racca, Bruno Gomes, Nicolas Guilbaud, and Patrick Calsou
- 2178** **A Novel Combination Treatment Targeting BCL- X_L and MCL1 for KRAS/BRAF-mutated and BCL2L1-amplified Colorectal Cancers**
Sung-Yup Cho, Jee Yun Han, Deukchae Na, Wonyoung Kang, Ahra Lee, Jooyoung Kim, Jieun Lee, Seoyeon Min, Jinjoo Kang, Jeesoo Chae, Jong-II Kim, Hansoo Park, Won-Suk Lee, and Charles Lee

Table of Contents

LARGE MOLECULE THERAPEUTICS


- 2191** Alpha Particle Enhanced Blood Brain/Tumor Barrier Permeabilization in Glioblastomas Using Integrin Alpha-v Beta-3-Targeted Liposomes
Anirudh Sattiraju, Xiaobing Xiong, Darpan N. Pandya, Thaddeus J. Wadas, Ang Xuan, Yao Sun, Youngkyoo Jung, Kiran Kumar Solingapuram Sai, Jay F. Dorsey, King C. Li, and Akiva Mintz

- 2201** Epidermal Growth Factor Receptor (EGFR)-targeted Photoimmunotherapy (PIT) for the Treatment of EGFR-expressing Bladder Cancer
 Reema Railkar, L. Spencer Krane, Q. Quentin Li, Thomas Sanford, Mohammad Rashid Siddiqui, Diana Haines, Srinivas Vourganti, Sam J. Brancato, Peter L. Choyke, Hisataka Kobayashi, and Piyush K. Agarwal

- 2215** Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer
Josep Tabernero, Atsushi Ohtsu, Kei Muro, Eric Van Cutsem, Sang Cheul Oh, György Bodoky, Yasuhiro Shimada, Shuichi Hironaka, Jaffer A. Ajani, Jiri Tomasek, Howard Safran, Kumari Chandrawansa, Yanzhi Hsu, Michael Heathman, Azhar Khan, Lan Ni, Allen S. Melemed, Ling Gao, David Ferry, and Charles S. Fuchs

CANCER BIOLOGY AND SIGNAL TRANSDUCTION

- 2223** The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy
Michael P. Sanderson, Marco H. Hofmann, Pilar Garin-Chesa, Norbert Schweifer, Andreas Wernitznig, Stefan Fischer, Astrid Jeschko, Reiner Meyer, Jürgen Moll, Thomas Pecina, Heribert Amhof, Ulrike Weyer-Czemilofsky, Stephan K. Zahn, Günther R. Adolf, and Norbert Kraut

- 2234** JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung Cancer
 Kazuhiko Shien, Vassiliki A. Papadimitrakopoulou, Dennis Ruder, Carmen Behrens, Li Shen, Neda Kalhor, Juhee Song, J. Jack Lee, Jing Wang, Ximing Tang, Roy S. Herbst, Shinichi Toyooka, Luc Girard, John D. Minna, Jonathan M. Kurie, Ignacio I. Wistuba, and Julie G. Izzo

- 2246** The Tumor-Suppressor Protein OPCML Potentiates Anti-EGFR- and Anti-HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
Elisa Zanini, Louay S. Louis, Jane Antony, Evdokia Karali, Imoh S. Okon, Arthur B. McKie, Sebastian Vaughan, Mona El-Bahrawy, Justin Stebbing, Chiara Recchi, and Hani Gabra

- 2257** ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer
Alan P. Lombard, Chengfei Liu, Cameron M. Armstrong, Vito Cucchiara, Xinwei Gu, Wei Lou, Christopher P. Evans, and Allen C. Gao

- 2267** Ormeloxifene Suppresses Prostate Tumor Growth and Metastatic Phenotypes via Inhibition of Oncogenic β -catenin Signaling and EMT Progression
Bilal Bin Hafeez, Aditya Ganju, Mohammed Sikander, Vivek K. Kashyap, Zubair Bin Hafeez, Neeraj Chauhan, Shabnam Malik, Andrew E. Massey, Manish K. Tripathi, Fathi T. Halaweish, Nadeem Zafar, Man M. Singh, Murali M. Yallapu, Subhash C. Chauhan, and Meena Jaggi

- 2281** Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions
Kush Dalal, Meixia Che, Nanette S. Que, Aishwariya Sharma, Rendong Yang, Nada Lallous, Hendrik Borgmann, Deniz Ozistanbullu, Ronnie Tse, Fuqiang Ban, Huifang Li, Kevin J. Tam, Mani Roshan-Moniri, Eric LeBlanc, Martin E. Gleave, Daniel T. Gewirth, Scott M. Dehm, Artem Cherkasov, and Paul S. Rennie

- 2292** Inactivation of the Kinase Domain of CDK10 Prevents Tumor Growth in a Preclinical Model of Colorectal Cancer, and Is Accompanied by Downregulation of Bcl-2
Louis-Bastien Weiswald, Mohammad R. Hasan, John C.T. Wong, Clarissa C. Pasilliao, Mahbuba Rahman, Jianhua Ren, Yaling Yin, Samuel Gusscott, Sophie Vacher, Andrew P. Weng, Hagen F. Kennecke, Ivan Bièche, David F. Schaeffer, Donald T. Yapp, and Isabella T. Tai


- 2304** Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma
 Salvia Jain, Abigail Washington, Rebecca Karp Leaf, Parul Bhargava, Rachael A. Clark, Thomas S. Kupper, Dina Stroopinsky, Athalia Pyzer, Leandra Cole, Myrna Nahas, Arie Apel, Jacalyn Rosenblatt, Jon Arnason, Donald Kufe, and David Avigan

Table of Contents

COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

- 2315** Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma



Joo Ern Ang, Akos Pal, Yasmin J. Asad, Alan T. Henley, Melanie Valenti, Gary Box, Alexis de haven Brandon, Victoria L. Revell, Debra J. Skene, Miro Venturi, Ruediger Rueger, Valerie Meresse, Suzanne A. Eccles, Johann S. de Bono, Stanley B. Kaye, Paul Workman, Udai Banerji, and Florence I. Raynaud

- 2325** Wnt Signaling Inhibition Promotes Apoptosis in Sarcomas—Response

Esther Martinez-Font, Oliver Vögler, Regina Alemany, and Antònia Obrador-Hevia

RETRACTION

- 2326** Retraction: EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E–Mutant NSCLC Cell Lines

LETTER TO THE EDITOR

- 2324** Wnt Signaling Inhibition Promotes Apoptosis in Sarcomas—Letter

François Bertucci, Pascal Finetti, and Daniel Birnbaum




AC icon indicates AuthorChoice

For more information please visit www.aacrjournals.org

ABOUT THE COVER

Quantitative liquid chromatography/mass spectrometry (LC/MS) metabolomics in two BRAF mutant human melanoma xenograft models (WM266.4 and A375), were used to select the metabolites increased or decreased in tumor versus non-tumor bearing animals, whose changes were reversed by the MEK inhibitor RO4987655. Of these 21 metabolites identified preclinically in these models that were sensitive to MEK inhibition, 15 on-treatment changes were significantly correlated with objective responses in patients with advanced melanoma treated with RO4987655 and seven metabolite levels had pre-treatment predictive value. For more details see the article by Ang and colleagues (beginning on page 2315).



Molecular Cancer Therapeutics

16 (10)

Mol Cancer Ther 2017;16:2045-2326.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/16/10>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/16/10>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.